Physician profile
Bryan Picou
NPI 1174969133
$3,518.06
in general payments reported to CMS, 2019-2025
36 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $728 · 2021: $658 · 2022: $373 · 2023: $323 · 2024: $473 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $421.54 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $374.34 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $327.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $255.92 | 2019-2024 | Verquvo, Belsomra, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.80 | 2020-2025 | Ofev, Jardiance |
| Novo Nordisk INC | $195.30 | 2020-2025 | Ozempic |
| Glaxosmithkline, LLC. | $182.12 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $181.30 | 2019-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $133.25 | 2024-2025 | Gvoke Hypopen, Keveyis |
| Sumitomo Pharma America, INC. | $112.44 | 2024-2025 | Gemtesa |
| Kerecis Limited | $92.95 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sanofi-Aventis U.S. LLC | $86.40 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.92 | 2020-2022 | |
| Amarin Pharma, INC. | $78.38 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.79 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.72 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $66.66 | 2022 | |
| Exact Sciences Corporation | $51.10 | 2023-2025 | Cologuard Collection Kit |
| Acera Surgical, INC. | $49.45 | 2024 | Restrata Wound Matrix |
| Axsome Therapeutics, INC. | $49.07 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.41 | 2020-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $43.81 | 2021-2024 | Rexulti |
| Amgen INC. | $41.76 | 2019-2023 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.73 | 2024-2025 | Caplyta |
| Abbvie INC. | $33.33 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $31.42 | 2023-2025 | Nuzyra, Xhance |
| Janssen Pharmaceuticals, INC | $27.09 | 2019 | |
| Convatec INC. | $19.54 | 2025 | |
| Organogenesis INC. | $17.34 | 2021 | |
| Blueprint Medicines Corporation | $17.17 | 2020 | |
| Eisai INC. | $16.75 | 2020 | |
| Medicure Pharma INC. | $15.94 | 2022 | |
| Mylan Specialty L.P. | $15.19 | 2021 | |
| Acadia Pharmaceuticals INC | $14.47 | 2019 | |
| Shield Therapeutics INC | $14.11 | 2024 | |
| Allergan, INC. | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Picou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.